Regioselective synthesis of water-soluble monophosphate derivatives of combretastatin A-1. (Q35743971)

10 August 2017

title

Regioselective synthesis of water-soluble monophosphate derivatives of combretastatin A-1. (English)

1 reference

10 August 2017

10

George R Pettit

1 reference

10 August 2017

Rajendra P Tanpure

1

1 reference

10 August 2017

Benson L Nguyen

2

1 reference

10 August 2017

Tracy E Strecker

3

1 reference

10 August 2017

Savannah Aguirre

4

1 reference

10 August 2017

Suman Sharma

5

1 reference

10 August 2017

David J Chaplin

6

1 reference

10 August 2017

Bronwyn G Siim

7

1 reference

10 August 2017

Ernest Hamel

8

1 reference

10 August 2017

John W Lippert

9

1 reference

10 August 2017

Mary Lynn Trawick

11

1 reference

10 August 2017

Kevin G Pinney

12

1 reference

10 August 2017

publication date

30 June 2011

1 reference

Journal of Natural Products

10 August 2017

published in

1 reference

10 August 2017

volume

74

1 reference

10 August 2017

issue

7

1 reference

10 August 2017

page(s)

1568-1574

1 reference

A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome

10 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3275140

Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3275140

Tumour targeting by microtubule-depolymerizing vascular disrupting agents

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3275140

27 July 2018

Vascular damaging agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3275140

Disrupting tumour blood vessels

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3275140

Differentiation and definition of vascular-targeted therapies.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3275140

Microtubules as a target for anticancer drugs

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3275140

Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3275140

Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3275140

In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3275140

Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3275140

Antineoplastic agents. 379. Synthesis of phenstatin phosphate

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3275140

Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3275140

Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3275140

Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3275140

Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3275140

Regio- and stereospecific synthesis of mono-beta-d-glucuronic acid derivatives of combretastatin A-1.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3275140

Antineoplastic agents. 552. Oxidation of combretastatin A-1: trapping the o-quinone intermediate considered the metabolic product of the corresponding phosphate prodrug.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3275140

Enhanced fluorescence detection of cis-combretastatins by post-column photolysis

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3275140

Oxidative metabolism of combretastatin A-1 produces quinone intermediates with the potential to bind to nucleophiles and to enhance oxidative stress via free radicals

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3275140

Sulforhodamine B colorimetric assay for cytotoxicity screening

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3275140

Vascular disrupting agents

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3275140

Design, synthesis, and biological evaluation of combretastatin nitrogen-containing derivatives as inhibitors of tubulin assembly and vascular disrupting agents

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3275140

Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3275140

Vinca alkaloids: anti-vascular effects in a murine tumour

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3275140

Antineoplastic agents. 443. Synthesis of the cancer cell growth inhibitor hydroxyphenstatin and its sodium diphosphate prodrug

25 September 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/21718055

12 December 2020

Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin

1 reference

https://pubmed.ncbi.nlm.nih.gov/21718055

12 December 2020

Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/21718055

12 December 2020

Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature

1 reference

https://pubmed.ncbi.nlm.nih.gov/21718055

12 December 2020

Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate

1 reference

https://pubmed.ncbi.nlm.nih.gov/21718055

12 December 2020

A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)

1 reference

https://pubmed.ncbi.nlm.nih.gov/21718055

12 December 2020

Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/21718055

12 December 2020

Identifiers

DOI

10.1021/NP200104T

1 reference

10 August 2017

1 reference

10 August 2017

1 reference